|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01558 HEC CJ PHARM
Nominal 
9.350 -0.230 (-2.401%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 2,454,762 | -23.504% | 6,294,585 | 3,744,952 | 913,788 | 2,348,113 |
| Cost of Sales | (505,530) | -21.631% | (1,308,821) | (898,878) | (430,089) | (351,547) |
| Gross Profit | 1,949,232 | -23.975% | 4,985,764 | 2,846,074 | 483,699 | 1,996,566 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (29) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 813,531 | -35.529% | 2,126,771 | 39,422 | (667,184) | 1,010,434 | |
| Taxation | (128,800) | -45.866% | (270,945) | 9,817 | 79,460 | (173,023) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 136,798 | 27,364 | 75 | 2,044 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 684,731 | -33.489% | 1,992,624 | 76,603 | (587,649) | 839,455 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 7,424 | -93.048% | 169,623 | 274,907 | 232,461 | 219,219 |
| Depreciation & Amortisation | 196,838 | 2.038% | 391,274 | 377,357 | 259,816 | 122,726 |
| Directors' Emoluments | -- | -- | 41,563 | 4,966 | 4,457 | 3,963 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 78.000 | -33.333% | 226.000 | 9.000 | -67.000 | 95.000 |
| DPS (cts) | 135.820 | -- | 0.000 | 0.000 | 0.000 | 10.000 |
| Dividend Payout Ratio (%) | 174.129% | -- | -- | -- | -- | 10.526% |
| Cash flow per share ($) | -- | -- | 1.901 | 1.932 | (0.753) | 1.474 |
| NBV per share ($) | 9.847 | -- | 9.018 | 6.688 | 6.601 | 5.558 |
| Remarks: | Real time quote last updated: 27/12/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 684,731 |
| %Change | -33.489% |
| EPS / (LPS) | RMB 0.780 |
| NBV Per Share (¥) | RMB 9.847 |